ProQR Therapeutics announced positive Phase 1 data for AX-0810, an RNA editing therapy targeting NTCP to reduce toxic bile acid buildup in the liver. The study in healthy volunteers showed dose-dependent biomarker changes indicating effective target engagement, with up to an 8-fold increase in serum bile acids and a favorable safety profile. These results support advancing the next-generation candidate AX-0811 and planning Phase 2 trials for biliary atresia, a severe liver disease. Full Phase 1 data and further clinical developments are expected by late 2026 and 2027.
Jyske Realkredit A/S announced fixed coupon rates for several bond series effective from July 1 to September 30, 2026. The rates range from 2.31% to 2.92% per annum depending on the bond series. This update informs investors about the expected return...
Jyske Realkredit A/S announced the fixed coupon interest rates for several bond series effective from July 1, 2026, to September 30, 2026. The rates range from 2.31% to 2.92% per annum depending on the bond series. This update informs investors about...
Nyrstar NV released a legal opinion addressing the impact of its potential dissolution and liquidation on ongoing criminal cases and its ability to pursue claims against responsible third parties. This follows a notice from the FSMA and aims to clari...
Nyrstar NV has published a legal opinion from external lawyers regarding the impact of a potential company dissolution and liquidation on an ongoing criminal procedure and the company's ability to protect its rights by possibly filing claims against ...
Oblenio Bio secured $62 million in a Series B funding round led by Pfizer Ventures to support clinical development of LBL-051, a tri-specific T-cell engager targeting autoimmune diseases. LBL-051 aims to reset the immune system by depleting B-cells a...
